Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 Jun;7(6):552-554.
doi: 10.1158/2159-8290.CD-17-0380.

Quantifying the Benefits of Genome-Driven Oncology

Alison M Schram  1 , David M Hyman  2   3
Affiliations
Comment

Quantifying the Benefits of Genome-Driven Oncology

Alison M Schram et al. Cancer Discov. 2017 Jun.

Abstract

<b/> The excitement surrounding genomically selected cancer therapy has led many to question whether this treatment paradigm is living up to its initial promise. The MOSCATO study suggests that a genome-driven strategy for cancer therapy improves outcomes in a significant minority of patients who undergo molecular screening. Cancer Discov; 7(6); 552-4. ©2017 AACR.See related article by Massard et al., p. 586.

PubMed Disclaimer

Comment on

  • High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.
    Massard C, Michiels S, Ferté C, Le Deley MC, Lacroix L, Hollebecque A, Verlingue L, Ileana E, Rosellini S, Ammari S, Ngo-Camus M, Bahleda R, Gazzah A, Varga A, Postel-Vinay S, Loriot Y, Even C, Breuskin I, Auger N, Job B, De Baere T, Deschamps F, Vielh P, Scoazec JY, Lazar V, Richon C, Ribrag V, Deutsch E, Angevin E, Vassal G, Eggermont A, André F, Soria JC. Massard C, et al. Cancer Discov. 2017 Jun;7(6):586-595. doi: 10.1158/2159-8290.CD-16-1396. Epub 2017 Apr 1. Cancer Discov. 2017. PMID: 28365644 Clinical Trial.

References

    1. Hyman DM, Taylor BS, Baselga J. Implementing Genome-Driven Oncology. Cell. 2017;168:584–99. - PMC - PubMed
    1. Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, Davies MA, et al. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. J Clin Oncol. 2015;33:2753–62. - PMC - PubMed
    1. Hyman DM, Solit DB, Arcila ME, Cheng DT, Sabbatini P, Baselga J, et al. Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. Drug Discovery Today. 2015;20:1422–8. - PMC - PubMed
    1. Tannock IF, Hickman JA. Limits to Personalized Cancer Medicine. New England Journal of Medicine. 2016;375:1289–94. - PubMed
    1. Tourneau CL, Delord J-P, Gonçalves A, Gavoille C, Dubot C, Isambert N, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. The Lancet Oncology. 2015;16:1324–34. - PubMed

LinkOut - more resources